Efficacy of co-created, culturally-sensitive intervention for type 2 diabetes self-management education in immigrants in Italy: The DiabEthic randomized clinical trial.

Diabetes Res Clin PractJul 28, 2026 (epub)
Clinical ResearchEndocrinology

Alessio Pellegrino, Laura Bonvicini, Alessio Petrelli et al.

✦ AI-curated · Sources linked

In 30 seconds

The DiabEthic trial evaluated a culturally sensitive intervention for diabetes self-management in 202 adult first-generation immigrants in Italy with type 2 diabetes. This randomized controlled trial found that the intervention group experienced a significant reduction in HbA1c of -0.70% compared to standard care at 12 months, indicating improved diabetes management.

Key findings

  • The intervention group had a HbA1c reduction of -0.70% compared to the control group.
  • Significant improvements were observed in waist circumference and triglycerides.
  • Changes in non-refined cereals consumption and waist circumference mediated 40% of the intervention's effect on HbA1c.
  • No significant changes were noted in blood pressure, body mass index, LDL, or physical activity.

Why it matters

This study highlights the importance of culturally tailored interventions in improving diabetes management among immigrant populations, which may enhance patient outcomes and adherence to treatment.

Source

PubMed · PMID 42520979

Published in Diabetes Res Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.